SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-21-000041
Filing Date
2021-09-14
Accepted
2021-09-14 17:29:36
Documents
12
Period of Report
2021-09-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20210914.htm   iXBRL 8-K 43421
  Complete submission text file 0001438533-21-000041.txt   184290

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20210914.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20210914_lab.xml EX-101.LAB 25154
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20210914_pre.xml EX-101.PRE 13044
5 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20210914_htm.xml XML 11268
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 211253293
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences